Siddharth Mittal

Siddharth Mittal has assumed the role of Managing Director and Chief Executive Officer of Syngene International effective 1 July 2026, succeeding Peter Bains. Mittal brings close to three decades of business leadership experience to the global contract research, development, and manufacturing organization (CRDMO).

Mittal joins Syngene from Biocon Limited, where he most recently served as the Managing Director and Chief Executive Officer. During his thirteen years at Biocon, Siddharth held the position of Chief Financial Officer, before being appointed Managing Director and CEO. During this period, he played a crucial role in shaping the company's strategic direction, strengthening commercial operations, and expanding its presence in global markets. He was instrumental in securing key regulatory approvals and successfully commercialising Biocon's GLP-1 portfolio across major international markets.

Mittal holds a Bachelor of Commerce degree from the Symbiosis College of Arts and Commerce, Pune, and is a chartered accountant from the Institute of Chartered Accountants of India, as well as a certified public accountant from Colorado, USA. Prior to joining Biocon, Mittal was Vice-President, Finance and Corporate Controller at Symphony Teleca, a leading US-based multinational IT company.

Career History

• Managing Director & Chief Executive Officer, Syngene International (July 2026–present)
• Managing Director & Chief Executive Officer, Biocon Limited
• Chief Financial Officer, Biocon Limited (2013–2019)
• Vice-President, Finance and Corporate Controller, Symphony Teleca
• Senior Finance Leadership roles (Finance Director), Xchanging Plc US subsidiary
• Audit Division, S.R. Batliboi & Co. (Indian arm of Ernst & Young), Bangalore

What Siddharth Mittal could bring to his role as MD & CEO of Syngene: Mittal's proven ability to lead transformational change across complex, science-driven organizations positions him well to drive Syngene's commercial acceleration and global expansion. His deep expertise in biosimilars development, GLP-1 therapeutic commercialization, and international regulatory navigation, honed during his tenure leading Biocon's biologics business, combined with his financial acumen and M&A experience, could unlock significant value creation opportunities in the CRDMO sector. His track record of building organizational capabilities and managing high-stakes global partnerships suggests he can sharpen Syngene's competitive edge while maintaining the scientific excellence and customer trust the organization has cultivated.

This is an automatically generated Light profile created by Executive Moves editorial systems from verified public announcements. Information is kept deliberately concise until the page is claimed and enriched.